The octopi at Tentarix Biotherapeutics are celebrating this morning.
AbbVie plans to pay $64 million upfront for two programs out of the San Diego biotech’s so-called Tentacles platform, spread across one target in oncology and the other in immunology, the drug developers said Thursday. If the Chicago-area Big Pharma wants to fully acquire the programs after the biologic candidates have been nominated, it will dish out further payments of undisclosed size.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.